Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

114.20

+0.33 (0.29%)

as of Jun 18, 2026, 11:15:03 pm Market Open.

161 watching

HOLD

Company is on watch list. Does not own shares. Current share price target on the street is ~$100. Is cheaper valued than rest of the market (12x earnings). Has lower patent rate than competitors.

TOP PICK

Acquisition from last year has expanded product offering. Covid-19 pandemic was hard on company, but is recovering now. Company is a defensive name as drug prices are inelastic (medications are hard to give up). Strong cash flow and dividend.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Mar 24/22, Up 5.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK has triggered its stop at $855. To remain disciplined we recommend covering the position at this time. This will result in a net investment gain of 8%, when combined with previous buy recommendations.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Mar 24/22, Up 13.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK is progressing well. To remain disciplined, we recommend trailing up the stop (from $80) to $85.

BUY

Reasonable and sustainable multiple of 12x and very good dividend. Major drug is patent-protected until at least 2026, plus great drugs in pipeline.

PAST TOP PICK

(A Top Pick May 08/20, Up 36%) Loves it. A bit pricey here. Model price of $122.65, a 31% upside. In bear markets, people go for predictable earnings. Good bear market stock. Wait for a pullback to buy, under $70. Over 3% yield.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Mar 24/22, Up 15%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK has achieved its $92.50 target. To remain disciplined, we recommend covering half the position at this time and trailing up the stop (from $74) to $80.

TOP PICK

Growth focused, but a real business. Safety. Second-largest in animal health, diversified oncology. Visibility and pricing power. Roche's miss in immunotherapy reinforces MRK's leadership position in that area. Not expensive. 13x earnings for near double-digit EPS growth. Yield is 3.09%. (Analysts’ price target is $96.34)

TOP PICK

Their major drug in oncology treats cancer and will earn $18 billion in revenue this year. Trades at 12x earnings and pays a large dividend. MRK has a strong balance sheet, their drug pipeline promises future growth, their balance sheet is strong, and they can resist hot inflation. (Analysts’ price target is $96.34)

BUY

options There's been a huge spike in options in healthcare stocks. Merck started seeing options activity in late March. Today sees 14,000 of the May $87.50 calls for $1.50.

BUY

Some growth, especially in its blockbuster drug, which makes up 1/3 of total revenue. An uncomfortable concentration, but the patents are long-dated. Good dividend, AAA balance sheet, reasonable multiple at 11x.

BUY

He's long this. You're finally getting a technical breakout. The stock is at the highest levels of the year. Take advantage of the valuation discount for the healthcare sector compared to the S&P.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O’Reilly With several developmental cancer drugs continuing to make good progress, we again reiterate this $195 billion marketcap global drug manufacturer as a TOP PICK. Recently reported earnings beat expectations by over 20% and the company is managing a ROE over 45%. Trading at 16x forward earnings, compared with its peers at 21x, it is good value here. It pays a good dividend, backed by payout ratio under 55% of cash flow. We recommend trailing up the stop (from $70) to $74, looking to achieve $92.50 -- upside potential of 15%. Yield 3.4% (Analysts’ price target is $92.38)

BUY

It trades at 12x earnings with a solid growth rate, based on their major oncology drug. Also, their drug pipeline is solid. Dividend is healthy.

HOLD

Good large cap with reasonable growth. Really likes its diversity. Oncology, diabetes, immunology, globally #2 in animal health. Competition from BMY and LLY. Lacklustre R&D. Happy to hold through the volatility.

Showing 31 to 45 of 252 entries

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Merck & Company (MRK)